 HENDERSON, Nev.--BUSINESS WIRE--Spectrum Pharmaceuticals NasdaqGS: SPPI, a biopharmaceutical company focused on novel and targeted oncology therapies, today announced additional exploratory data for poziotinib in non-small cell lung cancer NSCLC patients harboring HER2 exon 20 insertion mutations at the 2022 American Society of Clinical Oncology ASCO Annual Meeting being held in Chicago from June 3-7. In poziotinib treated patients with advanced NSCLC harboring HER2 exon 20 insertion mu 